OncoMatch/Clinical Trials/NCT07302347
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Is NCT07302347 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Pembrolizumab for malignant neoplasm.
Treatment: Pembrolizumab — Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Disease stage
Required: Stage IIB, IIC, III, IV
Stage IIB, IIC, III or IV cutaneous melanoma; locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma; locally-advanced, or metastatic solid malignancy; metastatic MCC (Stage IV)
Demographics
Prior therapy
Must have received: surgery — adjuvant
surgically completely resected ... melanoma
Must have received: locoregional therapy (surgery and/or radiation therapy) — locoregional
MCC that has recurred following standard locoregional therapy with surgery and/or radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07302347 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received surgery and locoregional therapy (surgery and/or radiation therapy).
What disease stage is eligible?
Stage IIB or IIC or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages